Eloxx Pharmaceuticals (NASDAQ:ELOX – Get Free Report) and Alpha Cognition (NASDAQ:ACOG – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.
Risk & Volatility
Eloxx Pharmaceuticals has a beta of -1960.42, indicating that its share price is 196,142% less volatile than the S&P 500. Comparatively, Alpha Cognition has a beta of 2.32, indicating that its share price is 132% more volatile than the S&P 500.
Valuation and Earnings
This table compares Eloxx Pharmaceuticals and Alpha Cognition”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Eloxx Pharmaceuticals | $6.36 million | 8.45 | -$5.99 million | ($1.54) | -8.64 |
| Alpha Cognition | $15.26 million | 12.24 | -$20.67 million | ($1.10) | -7.80 |
Eloxx Pharmaceuticals has higher earnings, but lower revenue than Alpha Cognition. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than Alpha Cognition, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
2.9% of Eloxx Pharmaceuticals shares are owned by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are owned by insiders. Comparatively, 8.6% of Alpha Cognition shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares Eloxx Pharmaceuticals and Alpha Cognition’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Eloxx Pharmaceuticals | N/A | N/A | N/A |
| Alpha Cognition | -153.61% | -54.60% | -43.47% |
Analyst Ratings
This is a summary of current recommendations and price targets for Eloxx Pharmaceuticals and Alpha Cognition, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Eloxx Pharmaceuticals | 1 | 1 | 3 | 2 | 2.86 |
| Alpha Cognition | 0 | 0 | 5 | 0 | 3.00 |
Eloxx Pharmaceuticals presently has a consensus target price of $38.33, suggesting a potential upside of 188.22%. Alpha Cognition has a consensus target price of $18.00, suggesting a potential upside of 109.79%. Given Eloxx Pharmaceuticals’ higher possible upside, equities research analysts clearly believe Eloxx Pharmaceuticals is more favorable than Alpha Cognition.
Summary
Eloxx Pharmaceuticals beats Alpha Cognition on 8 of the 14 factors compared between the two stocks.
About Eloxx Pharmaceuticals
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States.
About Alpha Cognition
Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Receive News & Ratings for Eloxx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eloxx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
